SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE.X is trending as the community rallies around the meme coin, expressing bullish sentiment and encouraging others to join before a potential surge. Talk centers on community growth, relentless promotion, and the expectation of significant gains. The coin's association with the popular "Rage Guy" meme and potential listing on major exchanges are also fueling excitement.

"What's Updog?" is a Community Led token.

UpDog

UpDog is trending as the community celebrates its joke-inspired roots and long-term presence on the Solana blockchain. Many are drawn to its dedicated community, locked liquidity, and association with the popular "What's UpDog?" meme, while others highlight its potential within the broader meme coin landscape.

Cadrenal Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing novel therapy. It develops tecarfarin, a novel therapy with orphan drug indication, designed for the prevention of systemic thromboembolism of cardiac origin in patients with end-stage renal disease and atrial fibrillation. The company was founded by Quang X. Pham and Matthew K. Szot on January 25, 2022 and is headquartered in Ponte Vedra, FL.

Cadrenal Therapeutics Inc

Cadrenal Therapeutics, Inc.

Cadrenal Therapeutics ($CVKD) is trending as traders discuss its bullish technical setup and potential for an upside breakout, fueled by recent news of the acquisition of anti-coagulant assets. The community highlights the momentum and strong buyer confidence, while also noting the healthcare technology niche and upcoming milestones for their drug Tecarfarin. Some are watching for volume to confirm the move, and analysts are noting high price targets for the stock.

Codatta

Codatta ($XNY.X) is trending amid discussions about its on-chain fingerprint verification launch and potential applications of its AI/data utility. The community is analyzing its chart patterns, with some pointing to bullish setups and expecting new highs, while others are watching key support levels for potential entry points. Sentiment is mixed, with some expressing excitement about its potential and others remaining cautious.

Derive is a decentralized protocol that creates programmable onchain options, perpetuals, and structured products.   Derive is deployed and operates on Derive Chain, an Ethereum rollup built using the OP stack and is the home of the Derive Protocol. It is a permission-less smart contract platform.  The Derive DAO earns trading fees from the Derive Protocol and gas fees from the Derive Chain, governed by DRV token holders. Trading fees accrue to an insurance fund to foster robustness of the protocol and rollup.  Derive has built an AI-powered trading app built for pro traders. In collaboration with Messari, Derive Pro translates market views into trades. The agent then prepares transactions for users and leverages smart contract wallets to make trades one-click, gasless and chainless. The app will support spot, perps and options trading on Derive, and will also plug in to spot AMMs on L2s like Optimism, Arbitrum and Base.

Derive

Derive (DRV.X) is trending as the community discusses its strong chart and potential for another leg up, with some highlighting treasury loop mechanisms like airdrops and buybacks. The community also notes ongoing consolidation and recent upward movement, with some suggesting potential buybacks are underway. Furthermore, the community is discussing the partnership of Synthetix and Derive to build derivatives on ETH L1.

ConocoPhillips is an exploration and production company, which engages in the exploration, production, transport, and marketing of crude oil, bitumen, and natural gas. It operates through the following geographical segments: Alaska, Lower 48, Canada, Europe, Middle East, and North Africa, Asia Pacific, and Other International. The Alaska segment explores for, produces, transports and markets crude oil, natural gas and NGLs. The Lower 48 segment consists of operations located in the 48 contiguous U.S. states and the Gulf of Mexico. The Canada segment refers to oil sands development in the Athabasca Region of northeastern Alberta and a liquids-rich unconventional play in western Canada. The Europe, Middle East, and North Africa segment includes operations in the Norwegian sector of the North Sea, the Norwegian Sea, Qatar, Libya, Equatorial Guinea and commercial and terminalling operations in the U.K. The Asia Pacific segment focuses on explorations and product operations in China, Indonesia, Malaysia, and Australia. The Other International segment handles exploration activities in Columbia and Argentina. The company was founded by Isaac Elder Blake on November 25, 1875 and is headquartered in Houston, TX.

Conoco Phillips

ConocoPhillips is trending due to unusual options activity signaling bullish sentiment and actionable alerts for call options, driving speculative interest. The community is also discussing the company's resilience amid volatile oil prices, strong balance sheet, and potential upside from the Marathon Oil acquisition. Discussions also include ConocoPhillips' LNG deals and analysts weighing in on the company's strengths and weaknesses compared to its peers.

Enanta Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery and development of small molecule drugs for the treatment of viral infections and liver diseases. It produces clinical candidates which targets respiratory syncytial virus (RSV), hepatitis B virus (HBV), and non-alcoholic steatohepatitis (NASH) diseases. The firm also conducts research in human metapneumovirus (hMPV) and SARS-CoV-2 (COVID-19). The company was founded by Peter O. Kliem Martin Karplus, James Hogle, Gerard Wagner, Peter M. Howley, and Gregory L. Verdine in 1995 and is headquartered in Watertown, MA.

Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals ($ENTA) is trending due to topline results from its Phase 2b study, with community members eagerly awaiting further details. Some speculate on the potential for significant gains depending on the results, especially related to viral load reduction. The company's work on zelicapavir, an oral RSV N-protein inhibitor, is also drawing attention, particularly its potential in the adult RSV therapeutics market.

Pangolin is a community-driven decentralized exchange for Avalanche and Ethereum assets with fast settlement, low transaction fees, and a democratic distribution–powered by Avalanche.

Pangolin

Pangolin crypto is trending amidst mixed sentiments; while some traders express excitement about potential breakouts and the upcoming V3 launch, others are calling it a scam coin, citing concerns about the project's fundamentals and past performance. The community is actively discussing potential price movements and whether it's time to buy or sell, with some highlighting its limited supply as a positive factor.

Assemble’s AI agent, News3(NS3), was developed with the goal of revolutionizing Web 3.0 journalism. NS3 delivers crypto and global economic trends quickly and clearly, and leverages advanced AI reasoning capabilities to analyze these trends, enabling market participants to make data-driven decisions. In particular, NS3 utilizes OpenAI’s latest reasoning model as its core engine to analyze crypto and economic trends, providing a range of insights including market psychology, past case analysis, future predictions, ripple effects, and investment strategies in 12 languages.

Assemble Protocol

Assemble Protocol ($ASM.X) is trending as traders discuss potential catalysts, including possible exchange listings and movements by large Asian investors. Some community members express optimism for a pump, citing the low market cap, while others remain cautious, pointing to past volatility and dilution concerns. Conversations also mention Assemble Protocol's AI integration and potential partnerships, with some hoping for a significant price increase soon.

Bilibili, Inc. is a holding company, which engages in the provision of online entertainment content. The firm enables broad video-based content consumption scenarios centered around professional user generated videos supplemented with live broadcasting, occupationally generated videos, or occupationally generated videos. The company was founded by Xu Yi in June 2009 and is headquartered Shanghai, China.

Bilibili Inc - ADR

BILIBILI INC.

BILI is trending as the community discusses its long-term chart accumulation and potential breakout, fueled by bullish sentiment towards Chinese companies and recent bullish call sweeps. Some traders are eyeing it as the next big China runner, while others point to technical indicators and monetization struggles. Discussions also include overnight trading activity and potential gap-ups.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wall Street Analysts Think Edgewise Therapeutics (EWTX) Could Surge 182%: Read This Before Placing a Bet

The mean of analysts' price targets for Edgewise Therapeutics (EWTX) points to an 182% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe Edgewise Therapeutics (EWTX) Could Rally 172.96%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 173% in Edgewise Therapeutics (EWTX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

All You Need to Know About Edgewise Therapeutics (EWTX) Rating Upgrade to Buy

Does Edgewise Therapeutics (EWTX) Have the Potential to Rally 174.68% as Wall Street Analysts Expect?

Edgewise Therapeutics Provides Corporate Update and Highlights Priorities for 2025

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming priorities for 2025. Edgewise Chief...

Edgewise Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13, 2025

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that Kevin Koch, Ph.D, President and Chief Executive Officer, will present at the 43rd...

US Futures Jump, Ignore Global Selloff While Focusing On Imminent Rate Cut

US Futures Jump, Ignore Global Selloff While Focusing On Imminent Rate Cut

 The last full week of 2024 started off with a burst of US exceptionalism which helped US equity futures shrug...

Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker)

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced positive topline results from the Phase 2 CANYON trial of sevasemten in individuals...

Edgewise Provides Statement Regarding Companys Relationship with Dr. Han Phan at Rare Disease Research

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided information regarding the companys relationship with Dr. Han Phan at Rare Disease...

Edgewise Therapeutics to Present at the Piper Sandler 36th Annual Healthcare Conference on December 3, 2024

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Piper Sandler 36th Annual Healthcare Conference on...

Edgewise Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of innovative treatments for severe, rare muscle disorders for which there is significant unmet medical need. Its platform utilizes custom-built throughput and translatable systems that measure integrated muscle function in whole organ extracts to identify small molecule precision medicines regulating key proteins in muscle tissue, initially focused on addressing rare neuromuscular and cardiac diseases. The company was founded by Badreddin Edris, Alan Russel and Peter A. Thompson in 2017 and is headquartered in Boulder, CO.

Edgewise Therapeutics Inc

Will the U.S. government shut down in 2025? 
 
*Powered by Polymarket

EWTX
Edgewise Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest EWTX News

EWTX Edgewise Therapeutics Inc